RxDoctor Payments Data

Casey Starks, MD

Family Medicine · Douglas, WYNPI 1316205677

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by GSK at 33.0% of the total. Reporting peaked in 2022 at $181 and has fallen 83.2% since, to $30 in 2025.

$736in general payments, 2019–2025

Across 45 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$243
  • Lilly USA, LLC$76
  • Amgen$65
  • Novo Nordisk$60
  • Abbott$55
  • Sanofi-aventis U.S. LLC$42
  • plus $196 from 10 others

What the payments were for

  • Food & beverage$736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$736 in reported general payments places this provider in the 80th percentile of 237 family medicine providers in Wyoming.

See all family medicine providers in Wyoming

Medicare billing

Part B allowed, 2024
$47,853
Medicare patients
125
Services billed
821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$30,723
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,805
OzempicSemaglutide13$13,544
MounjaroTirzepatide13$13,449
XareltoRivaroxaban15$9,930
Atorvastatin Calcium148$1,841
Levothyroxine Sodium166$1,569
Tramadol Hcl62$1,495
Pantoprazole Sodium56$1,383
SynthroidLevothyroxine Sodium11$1,194
Rosuvastatin Calcium36$1,162
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,065
Omeprazole47$1,029
Losartan Potassium60$932
Amlodipine Besylate75$802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$243$15,80515 claims
Novo NordiskOzempic$60$13,54413 claims
Lilly USA, LLCMounjaro$76$13,44913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 237 family medicine providers in Wyoming.

Other family medicine in Douglas

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →